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A B S T R A C T
Diabetes mellitus is a metabolic disorder primarily characterized by elevated blood glucose levels and by microvas-
cular and macrovascular complications which increase the morbidity and mortality. The aim of this study was to assess
whether in high risk patients with type 2 diabetes mellitus whose blood pressure and lipid levels are well controlled still
exist risk factors for microvascular changes and target organ damage (nephropathy and retinopathy). In this case con-
trol retrospective study 326 patients (111 with nephropathy and/or retinopathy and 215 controls) were enrolled. Nephro-
pathy or retinopathy was present in 10.1% and 26.9% cases, respectively. Only 71% of patients (no significant difference
between cases and controls) were treated with antidiabetic drugs. Therefore their diabetes was not properly controlled
(hemoglobin A1c was 7.96% in cases and 7.58% in controls). Patients with microvascular changes had significantly lon-
ger diabetes than the controls (p < 0.05) but there were no significant differences between these two groups concerning
lipids concentrations. Statins and fibrates were used by significantly less (p < 0.05) patients with microvascular compli-
cations than by those without them (21.6% vs. 36.3% and 1.8% vs. 17.2% respectively). The results of this study suggest
that the duration of the disease and adequate control of glycaemia in patients with type 2 diabetes mellitus are more im-
portant for microvascular complications than the serum lipoproteins levels. Lipid-lowering treatment might have an im-
pact on microvascular complications in patients with type 2 diabetes, irrespectively of their serum lipid levels.
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Introduction
Diabetes is a metabolic disorder primarily character-
ized by elevated blood glucose levels and by microvascu-
lar and macrovascular complications. These complica-
tions increase the morbidity and mortality associated
with the disease and reduces substantially the quality of
life.
Cardiovascular disease (CVD) are the most important
cause of death in Croatia and worldwide1. It is also the
major cause of death in patients with type 2 diabetes
mellitus because more than 60 % of patients with type 2
diabetes die from myocardial infarction or stroke2.
On the other hand, diabetes mellitus and dyslipidae-
mia are, together with hypertension, smoking and obe-
sity, the most important risk factors for coronary heart
disease (CHD) and myocardial infarction (MI) as well as
cerebrovascular disease3–6. An association between the
complications of diabetes and elevated blood glucose lev-
els was postulated many decades ago and revaluated in
the follow up studies7–9.
However, observational epidemiologic data published
in the last three decades suggest that not only lower
blood glucose levels, but even more, lower blood pressure
and lower serum lipids might be associated with a lower
incidence of micro- and macrovascular complications in
patients with diabetes.
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The United Kingdom prospective Study (UKPDS)
was the first large intervention study which provided the
evidence that tight glucose control could be effective in
reducing the risk of major microvascular endpoints in pa-
tients with type 2 diabetes but the effects on CVD risk
(macrovascular endpoints) were modest and did not reach
the statistical significance8. Recently, three major trials,
the Veterans Affairs Diabetes trial (VADT)10, the Action
to Control Cardiovascular risk in Diabetes (ACCORD)11,
and the Action in Diabetes and vascular Disease (AD-
VANCE)12 evaluated the impact of attaining good blood
glucose control in older patients with diabetes and high
cardiovascular risk and reported no significant decrease
in primary cardiovascular endpoints with intensive glu-
cose control.
Nevertheless, large observational studies show that
both elevated triglycerides (either fasting or non-fasting)
and reduced plasma levels of high-density lipoprotein
cholesterol (HDL-C) are associated with increased cardio-
vascular risk, even at or below recommended low-density
lipoprotein cholesterol (LDL-C) levels13–16. In patients
with type 2 diabetes mellitus already the UKPDS study
has identified decreased HDL-C as the second most im-
portant coronary risk factor, after elevated LDL-C8.
Much more recently, it has been established that
dyslipidaemia is important not only for macrovascular
changes, but also in the pathogenesis of diabetic micro-
vascular disease17. Elevated levels of total cholesterol as
well as LDL-C are associated with the increased risk for
proliferative diabetic retinopathy, and elevated levels of
TG appear to be associated with progression of albumi-
nuria18.
The aim of this study was to assess whether in high
CVD risk patients with type 2 diabetes mellitus whose
blood pressure and lipid levels are well controlled still
exist risk factors that might precipitate microvascular
changes and target organ damage, particularly nephro-
pathy and retinopathy.
Methods
The study was a case-control retrospective study and
it was conducted in University Hospital Center Zagreb.
Patients population and inclusion criteria
Cases and controls were high risk patients (dyslipi-
demia + arterial hypertension ± target organ damage as
defined bellow) with type 2 diabetes, and with optimal
blood pressure (BP) control (defined as BP £140/90
mmHg) as well as with LDL-C less than 3.4 mmol/L. Ar-
terial hypertension was defined as BP before the treat-
ment ³ 140/90 mmHg or usage of antihypertensive drugs.
Blood pressure was measured according to recent guide-
lines19. Cases were patients with diabetes mellitus type 2
and at least one recorded microvascular complication
(nephropathy, retinopathy, diabetic macular edema).
Controls were patients with type 2 diabetes mellitus
with no documented evidence of any microvascular com-
plications.
Case definitions
Nephropathy was defined as proteinuria >300 mg/L,
albuminuria, or estimated glomerular filtration rate <60
ml/min/1.732. Albuminuria was measured and defined as
> 30 mg/24 h in a 24-hour urine. A low glomerular fil-
tration rate was estimated by the MDRD formula. Se-
rum creatinine level was detected by colorimetric Jaffe
method.
Retinopathy was defined as laser treatment for diabe-
tic retinopathy or Diabetic Retinopathy Disease Severity
Scale 3,4 or 5 shown by dilated ophthalmoscopy; or
maculopathy defined as moderate or severe using Dia-
betic Macular Edema Disease Severity Scale.
Measurements
All data were obtained from reviews of medical re-
cords. The lipid values were from blood taken in the
fasting state. Total cholesterol, HDL-C, LDL-C (mea-
sured directly or calculated) and triglycerides were as-
sayed within the 6 months prior to the date of the index
visit. Data obtained included age, sex, duration of diabe-
tes, body weight, height, ethnicity, history of hyperten-
sion, blood pressure, current medical treatment, medica-
tions, smoking, cardiovascular diseases, fasting blood
glucose, and hemoglobin A1c.
Statistical analysis
Data are expressed as means ± standard deviation
(SD). All data were analyzed by two-way ANOVA or the
Student’s t-test as appropriate. A p value less than 0.05
was considered to be statistically significant.
Results
A total of 326 patients were enrolled who matched in-
clusion criteria. Among them 111 cases were matched by
gender and age to 215 controls. Nephropathy was pres-
ent in 33 cases and retinopathy in 88 cases (10.1% and
26.9% respectively). Characteristics of the cases and con-
trols are shown in Table 1.
Surprisingly only about 71% patients with type 2 dia-
betes, (no significant difference between cases and con-
trols), were treated with antidiabetic drugs. This is the
reason why their diabetes was not satisfactory regulated,
with mean hemoglobin A1c 7.96% for cases and 7.58% for
controls (7.71% overall).
As expected, 78.4% cases and 63.3% controls had arte-
rial hypertension which was well controlled (BP<140/90
mmHg) in all of them.
Patients with microvascular diabetes complications
had significantly longer (p<0.05) diabetes than the con-
trols but there were no significant differences between
these two groups concerning their lipids concentrations.
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Statins and fibrates were used by significantly less
(p<0.05) patients with microvascular complications than
those without them (21.6% vs. 36.3% and 1.8% vs. 17.2%
respectively).
Discussion
Our results suggest that adequate control of glyca-
emia in patients with type 2 diabetes mellitus is more im-
portant for microvascular complications than the serum
lipoproteins levels. Microvascular complications of diabe-
tes remain the leading causes of blindness and renal fail-
ure in the developed world and it seems that they are
much more closely associated with hyperglycemia than
macrovascular complications20.
Intensive glucose control in the ADVANCE study
which included 11140 patients with type 2 diabetes
showed a reduction in the development of new or worsen-
ing of existing nephropathy and modest, but significant
reduction in new-onset microalbuminuria. However, no
significant benefit on retinopathy could be proven21. The
UKPDS, one of largest studies of glycaemia control in pa-
tients with type 2 diabetes, has shown that tighter glu-
cose control did not reduce the incidence of major renal
outcomes, but has found evidence of a reduction in the
development of microalbuminuria and overt proteinuria
after a prolonged follow-up period21. A clear reduction in
nephropathy demonstrated in the ADVANCE trial is im-
portant, because indexes of renal impairment are strong-
ly associated with the future risk of major vascular
events, end-stage renal disease, and death in patients
with diabetes22.
Intensive glycaemia therapy significantly reduced the
risk of progression of diabetic retinopathy in the AC-
CORD Eye study23. ACCORD eye study provides evi-
dence that the beneficial effect of intensive glycaemia
therapy on retinopathy progression, in patients with
type 2 diabetes that was newly diagnosed or not yet ac-
companied by hypertension, lipid abnormalities, or es-
tablished CVD, applies also to patients with type 2 diabe-
tes with characteristics similar to those enrolled in the
ACCORD trial, who were older and at greater cardiovas-
cular risk24–26. The ACCORD trial demonstrated that
fenofibrate, when added to statin therapy, slows the pro-
gression of diabetic retinopathy in patients with type 2
diabetes.
Atherogenic dyslipidaemia, characterized by elevated
triglycerides and low levels of HDL-C, is very common in
patients with type 2 diabetes mellitus and metabolic syn-
drome and is associated with macrovascular and micro-
vascular complications16, 27. It has been shown that such
dyslipidaemia might play an important role in the patho-
genesis of diabetic microvascular disease28. High levels of
triglycerides seem to be associated with an increased risk
for proliferative diabetic retinopathy and elevated levels
of total cholesterol as well as LDL-C may be associated
with the development of retinal hard exudates and dia-
betic maculopathy23, 29–31. The severity of retinopathy
was positively associated with the levels of serum triglyc-
erides, but negatively associated with HDL-C in the Dia-
betes Control and complications Trial/ Epidemiology of
Diabetes Interventions and complications Study32.
Many epidemiological studies have found an associa-
tion between elevated levels of triglycerides and progres-
sion of albuminuria, a first marker of diabetic nephro-
pathy33, 34. However, the association between HDL-C
levels and nephropathy has been less clear. Some of the
published data suggest that higher HDL-C levels may be
protective against nephropathy35.
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TABLE 1
DESCRIPTIVE STATISTICS OF SUBJECTS INCLUDED IN THE STUDY
N
Cases Controls
111 215
Demographics
Lipids
Males [N, (%)] 62 (55.9%) 111 (51.6%)
Age,years (mean, SD) 66.59 (8.95) 62.09 (10.56)
*Diabetes duration, years (mean, SD) 14.29 (9.03) 5.25 (5.48)
Total cholesterol (mmol/L) 5.07 (1.28) 4.68 (1.11)
LDL-cholesterol (mmol/L) 2.74 (0.62) 2.46 (0.79)
HDL-cholesterol (mmol/L) 1.25 (0.36) 1.26 (0.41)
Triglycerides (mmol/L) 1.98 (1.13) 2.08 (1.49)
*Hemoglobin A1C 7.96% (1.41%) 7.58% (1.52%)
Medication *Fibrate use [N, (%)] 2 (1.8%) 37 (17.21%)
*Statin use [N, (%)] 24 (21.62%) 78 (36.28%)
antidiabetic drugs use [N, (%)] 79 (71.17%) 154 (71.63%)
Clinical condition Nephropathy [N, (%)] 33 (29.73%) 0
Retinopathy [N, (%)] 88 (79.28%) 0
Hypertension [N, (%)] 87 (78.38%) 136 (63.26%)
* significantly different between groups
Our patients were high risk patients having several
cardiovascular risk factors. Most of them were almost op-
timally regulated concerning their serum lipid levels and
blood pressure value but their glucose regulation was in-
sufficient. Therefore their target organ damage pre-
sented here as microvascular complications (nephro-
pathy and retinopathy) are most probably related to
their relatively poor glycemic control. Also, much less of
them were treated with statins and fibrates than the con-
trols suggesting that lipid-lowering treatment might
have an impact on microvascular complications of type 2
diabetes irrespectively of the serum lipid levels. So far,
the effect of statin therapy on diabetic retinopathy has
been inconclusive. The Collaborative Atorvastatin Dia-
betes Study (CARDS) showed no significant benefit on
the progression of diabetic retinopathy with atorvasta-
tin, but other small studies have shown a reduction in
the severity of macular exudates associated with statin
therapy36, 37. Beneficial effect of lipid-lowering treatment
was demonstrated in experimental models but also in
some clinical studies38. FIELDS study suggested that
fibrates have beneficial effects on the development of
microvascular complications (nephropathy and especial-
ly retinopathy) in patients with diabetes, particularly on
the requirement for first laser treatment and macular
oedema. In a recent review, Kouroumichakis and col-
leagues summarised the data from experimental and
clinical studies on the emerging therapeutic potential of
fibrates in diabetic nephropathy39. Fibrates like statins
may act to decrease the progression of diabetic micro-
vascular complications not only through their lipid-low-
ering effects, but even more via their pleiotropic effects.
In general, data indicate that atherogenic lipid profile
(low HDL-C, elevated triglycerides) could not be directly
associated so far to diabetic nephropathy or retinopathy.
LDL-C levels of our patients were in recommended range
for high risk diabetic patients40.
Our study has some potential limitations. It was per-
formed on a relatively small number of hospitalized pa-
tients. The influence of other drugs on the results which
the patients were receiving (eg. RAS blockade) cannot be
excluded.
Conclusion
The results of this study suggest that the duration of
diabetes and adequate control of glycaemia in patients
with type 2 diabetes mellitus are more important for
microvascular complications than the serum lipoproteins
levels. The obtained results also indicate that lipid-low-
ering treatment might have an impact on microvascular
complications in patients with type 2 diabetes irrespec-
tively of the serum lipid levels.
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^IMBENICI RIZIKA ZA MIKROVASKULARNE ATEROSKELROTSKE PROMJENE U BOLESNIKA SA
[E]ENOM BOLESTI TIPA 2
S A @ E T A K
[e}erna bolest obilje`ena je povi{enim razinama glukoze u krvi te razvitkom mikrovaskularnih i makrovaskularnih
komplikacija koje su uzrok pove}anom morbiditetu i mortalitetu. Cilj je ovog istra`ivanja bio istra`iti da li u visoko
rizi~nih bolesnika sa tipom 2 {e}erne bolesti i dobro kontroliranim arterijskim tlakom i lipidima u serumu postoje
rizi~ni ~imbenici koji mogu biti uzrokom mikrovaskularnih promjena i posljedi~nog o{te}enja ciljnih organa, posebno
nefropatije i retinopatije. U ovo “case-control” retrospektivno ispitivanje uklju~ili smo sveukupno 326 ispitanika (111
sa nefropatilom i/ili retinopatijom i 215 bolesnika bez tih komplikacija – kontrolna skupina). 10,1% ispitanika imalo je
nefropatiju, a 26.9% imalo je retinopatiju. Samo 71% ispitanika (bez zna~ajne razlike me|u skupinama) bilo je lije~eno
antidijabeticima. Stoga ne ~udi da im je regulacija glukoze u krvi bila nedostatna (hemoglobin A1c bio je 7.96% u
bolesnika sa nefro/retinopatijom, a 7.58% u onih kontrolne skupine). Bolesnici s mikrovaskularnim komplikacijama u
usporedbi s onima iz kontrolne skupine rje|e su koristili statine (21.6% vs. 36.3%) i fibrate (1.8% vs. 17.2%). Bolesnici
sa mikrovaskularnim promjenama bolovali su od dijabetesa zna~ajno dulje nego oni iz kontrolne skupine (p < 0.05) ali
nije bilo razlike u koncentracijama lipida izme|u te dvije skupine. Rezultati na{eg istra`ivanja ukazuju da su u bo-
lesnika sa tipom 2 {e}erne bolesti za razvitak mikrovaskularnih komplikacija va`niji trajanje bolesti i odgovaraju}a
kontrola glikemije nego li koncentracije lipoproteina u serumu. Primjena lijekova za sni`avanje lipida u krvi mo`e imati
u~inak na mikrovaskularne komplikacije u bolesnika sa {e}ernom bole{}u tipa 2 neovisno o koncentracijama lipida u
serumu.
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